NCT06785090View on ClinicalTrials.gov

Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2024

Conditions
CataractCystoid Macular Edema After Phacoemulsification
Interventions
DRUG

Bromfenac

Bromfenac is a non-steroidal anti-inflammatory drug (NSAID) formulated as a 0.09% ophthalmic solution. It is administered to reduce inflammation and prevent cystoid macular edema (CME) following cataract surgery.

DRUG

Moxifloxacin 0.5% ophthalmic solution

antibiotic, standard postoperative care regimen

DRUG

Dexamethasone phosphate 0.1%

steroid, standard postoperative care regimen

Trial Locations (1)

10001

College of Medicine, University of Baghdad, Baghdad

All Listed Sponsors
lead

Inas Abd

OTHER

NCT06785090 - Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery | Biotech Hunter | Biotech Hunter